首頁 > 市場調查報告書 > 醫療設備

體外診斷婦科治療

市場調查報告書

商品編碼

1733168

全球子宮頸發育不良市場規模（按診斷、最終用戶、地區、範圍和預測）

Global Cervical Dysplasia Market Size By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), By Geographic Scope And Forecast

出版日期: 2025年04月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

子宮頸發育不良市場規模及預測

2024 年子宮頸發育不良市場規模價值 5.2268 億美元，預計到 2032 年將達到 8.5506 億美元，2026 年至 2032 年的複合年成長率為 7%。

消費者對子宮頸癌認知的提高促進了子宮頸發育不良市場的成長。此外，政府在疫苗接種、社會動員、篩檢和社區教育方面的舉措，以及 HPV 感染的增加，導致子宮頸發育不良的診斷率增加。本研究報告對子宮頸發育不良市場進行了全面評估。它對細分市場、市場相關趨勢、市場促進因素、限制因素、機會、競爭格局等進行了詳細的分析。

全球子宮頸發育不良市場定義

子宮頸發育不良是一種癌前病變，以子宮頸細胞異常生長為特徵。子宮頸發育不良也稱為子宮頸上皮內瘤。透過治療和定期檢查，您可以在癌症發展之前進行預防。子宮頸發育不良可發生在任何年齡，但最常見於 25 至 35 歲的女性。子宮頸發育不良是一種由人類乳突病毒 (HPV) 感染引發的性行為感染傳染病。沒有任何病徵，疾病為無綜合症。

根據感染細胞的類型，子宮頸發育不良分為腺泡細胞病變和上皮內病變兩種。此疾病可以透過子宮頸抹片檢查、HPV檢測和陰道鏡檢查來診斷。子宮頸發育不良是一種可以透過破壞和切除異常區域來治療的疾病。三種標準治療方法分別是手術、放射線治療、化療、藥物療法、消融療法和切除術（切除異常區域）。治療方法方法多種多樣，所需的手術方法根據癌症的進展和惡性程度而有所不同。

VMR 內部

產業報告中有哪些內容？

我們的報告包含可操作的數據和前瞻性的分析，可協助您制定宣傳方案、建立商業計劃、組織簡報或撰寫提案。

全球子宮頸發育不良市場概況

子宮頸發育不良是癌症診斷和治療領域成長最快的細分市場之一。子宮頸癌處於癌前階段，如果及早發現，可以有效治癒。消費者對此的認知不斷提高，導致預測期內對子宮頸篩檢測試的需求增加。此外，各已開發國家的政府機構正在實施篩檢計劃，以降低死亡率，改善公民的生活品質。此外，政府協會關於早期發現包括子宮頸發育不良在內的慢性疾病的建議是預測期內推動整個子宮頸發育不良市場發展的主要因素之一。

也存在一些限制市場成長的限制和障礙。等候核准、由於監管合規耗時而導致的藥物不可用以及子宮頸發育不良市場研發所需的高成本等因素都是阻礙全球子宮頸發育不良市場整體成長的潛在限制因素。然而，技術的不斷發展和新興市場的尚未開發的潛力提供了有利可圖的成長機會。

Growing consumer awareness regarding cervical cancer has led to risen growth of the Cervical Dysplasia Market. Furthermore, the government initiatives on vaccination, social mobilization, screening, and community education, and the increasing occurrence of HPV infection have also led to an expansion in the diagnosis of Cervical Dysplasia. The Global Cervical Dysplasia Market report provides a holistic evaluation of the market. The report provides an indepth analysis on the segments, market related trends, market drivers, restraints, opportunities along with the competitive landscape.

Global Cervical Dysplasia Market Definition

Cervical Dysplasia is a precancerous condition identified by abnormal growth of cells on the cervix. Cervical Dysplasia is also recognized as cervical intraepithelial neoplasia. It can be rectified before it becomes cancerous, by treatment and regular diagnosis. It usually strikes women of any age but more frequently between 25 to 35 years of age in women. Cervical Dysplasia is a sexually communicated disease-induced due to Human papillomavirus (HPV) infection. It does not show any symptoms, they are asymptomatic.

Cervical Dysplasia is classified in two varieties based on the type of cells it affects, involves glandular cell lesions and intraepithelial lesions. This condition can be diagnosed by a Pap test, HPV test, and colposcopy. Cervical Dysplasia is a condition that can be treated by the destruction and removal of the abnormal area. TSurgery, radiation therapy, chemotherapy, or medication combinations, ablation therapy, and resection (expulsion of the aberrant region) are the three types of standard treatment. There are various sorts of treatment alternatives, and the kind of surgical technique required relies on the stage and grade of cancer growth.

What's inside a VMR

industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cervical Dysplasia Market Overview

Cervical Dysplasia makes for one of the fastest-growing market segments in the area of cancer diagnosis and treatment. Cervical cancer is a precancerous stage and it can be effectively cured by early detection. Growing consumer awareness in this regard has headed to improved demand for cervical screenings in the forecast period. Moreover, government organizations in various developed countries administer screening programs in order to enhance the quality of life of the population by reducing the mortality rate. Furthermore, recommendations from government associations for early detection of chronic diseases including Cervical Dysplasia is one of the primary factors that is driving the overall Cervical Dysplasia Market over the forecast period.

There are certain constraints and barriers experienced that will limit the market growth. The factors such as pending approvals, unavailability of a therapeutic drug due to time-consuming regulatory compliance, and the high cost required for research and development in the market for Cervical Dysplasia are the potential restraints hampering the overall growth of the global Cervical Dysplasia Market. Nevertheless, the continuous developments in technologies, and untapped potential in emerging markets offer favorable growth opportunities.

Global Cervical Dysplasia Market: Segmentation Analysis

The Global Cervical Dysplasia Market is Segmented on the basis of Diagnostic, End-User, And Geography.

Cervical Dysplasia Market, By Diagnostic

Diagnostic Tests
Diagnostic Devices

Based on Diagnostic, the market is bifurcated into Diagnostic Tests, Diagnostic Devices. The diagnostic tests segment holds the largest market share during the forecast period. The factors that can be attributed to its efficacy, flexibility, reimbursement policies, and cost-effectiveness are accelerating the demand for this segment.

Cervical Dysplasia Market, By End-User

Hospitals
Diagnostic Centers
Ambulatory Surgical Centers
Others

Based on End-User, the market is bifurcated into Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, and Others. The hospital segment accounts for the largest market share through the forecast years. The factors that can be attributed to the availability of technologically advanced diagnostic devices and tests and the presence of various reimbursement policies enhance the demand for this segment.

Cervical Dysplasia Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of regional analysis, the global Cervical Dysplasia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America holds the largest market share. The technological advancements, increase in prevalence of various associated diseases, rising awareness and screening programs, and ongoing projects will boost the market in the North American region.

Key Players

The "Global Cervical Dysplasia Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as QIAGEN, F. Hoffmann La-Roche Ltd., Quest Diagnostics, Becton, Dickinson and company, Abbott Healthcare Pvt. Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally are also included in the competitive landscape section.

Key Developments

Both ASKA Pharmaceutical and KinoPharma, both Japanese pharmaceutical giants, agreed to a partnership agreement in January 2020 for the development and commercialization of medication candidates for cervical dysplasia in the market, which is now in the preclinical phase at KinoPharma. As part of the arrangement, ASKA will acquire exclusive rights to distribute the drug in Japan and will assist in the co-development of prospective therapeutic candidates in the future, while KinoPharma will earn upfront payments for the exclusive licencing.

1 INTRODUCTION OF GLOBAL CERVICAL DYSPLASIA MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CERVICAL DYSPLASIA MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL CERVICAL DYSPLASIA MARKET, BY DIAGNOSTIC

5.1 Overview
5.2 Diagnostic Tests
- 5.2.1 HPV Test
- 5.2.2 Pap Smear Test
- 5.2.3 Biopsy Test
5.3 Diagnostic Devices
- 5.3.1 Colposcope

6 GLOBAL CERVICAL DYSPLASIA MARKET, BY END-USER

6.1 Overview
6.2 Hospitals
6.3 Diagnostic Centers
6.4 Ambulatory Surgical Centers
6.5 Others

7 GLOBAL CERVICAL DYSPLASIA MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East

8 GLOBAL CERVICAL DYSPLASIA MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 QIAGEN
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 F. Hoffmann La-Roche Ltd.
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Quest Diagnostics
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Becton, Dickinson and company
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Abbott Healthcare Pvt. Ltd
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 OncoHealth Corporation, Inc.
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Hologic, Inc.
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments